Loading...

372 posters, 1 audios, 13 topics, 29 sessions, 1,035 authors, 449 institutions

ePostersLive by SciGen Technologies S.A. All rights reserved.

2362742

Paradoxical Failure of Sugammadex Reversal Rescued by Neostigmine: A Case Report

Poster Presenter

Jake Rodriguez

Authors

Jake Rodriguez, Seiha Kim

Affiliations

null,

Part of Topic

Late Breaking Medically Challenging Cases

Paradoxical Failure of Sugammadex reversal rescued by Neostigmine: A Case Report

BACKGROUND: Sugammadex is considered the gold standard for rocuronium reversal. This provides an exemplary case of reversal failure. Clinicians need to retain proficiency with traditional AChE inhibitors as an encapsulation failure backup.

 

Case Description

1.41-year-old, 57.5 kg female w/ PMH significant  for AS, Psoriatic Arthritis, SLE, CKD3b, Peripheral Neuropathy presents for a diagnostic laparoscopy for endometriosis under general anesthesia.
2.Autoimmune/Rheumatologic Workup: Diagnosed prior to 2022, managed w/ Rinvoq and hydroxychloroquine; recent labs showing normal inflammatory markers [CRP, ESR].
3.Patient intubation facilitated with rocuronium
4.Monitoring was guided by standard quantitative TOF peripheral nerve stimulation.
5.Sugammadex 200 mg administered intravenously. No clinical arousal or TOF improvement after five minutes.
6.A second 200 mg dose of Sugammadex was administered. After a 20-minute observation period, the patient remained severely weak with a rapid respiratory rate and low tidal volume, despite a total dose of 400 mg (approximating 8 mg/kg).

 

RESULTS

•Suspecting Sugammadex failure, the team used traditional reversal using Neostigmine (5 mg) and glycopyrrolate (0.4 mg).
•Following administration, the patient spontaneously awoke and began breathing.
•Successfully extubated and transferred to the PACU with no signs of residual blockade. The success of neostigmine confirmed the neuromuscular junction was anatomically intact and receptive.
 
•Potential Mechanisms for failure: Drug-Drug interactions displacing rocuronium, altered patient pharmacokinetics, NMJ transmission failure.
•No off-label or investigational drugs were used.
Sugammadex & Neostigmine
asraspring2026 banner
Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.